Pharma Due Diligence: Secure Your Investments with OSICS NetworkTHE OSICS NETWORK
The Importance of Specialized Due Diligence in Pharma & Biotech
Every acquisition in the pharmaceutical and biotech sectors represents a strategic growth opportunity—but also a significant risk if not properly assessed. In this highly regulated and complex environment, the true value of a target company depends as much on the strength of its industrial operations and quality system as on its financial performance. A generic approach is not enough: Due Diligence must be specialized, rigorous, and perfectly tailored to the sector’s specifics.
OSICS Network provides Due Diligence designed to meet these high standards. Our network of more than 120 senior consultants—former operational leaders and sector experts—brings a holistic view that anticipates both critical industrial risks, potential compliance gaps, and value creation opportunities. Our approach goes beyond evaluating visible elements: we are committed to understanding the deep dynamics that will drive integration success and future value creation. With this integrated expertise, our Private Equity clients make safer decisions that are better aligned with their medium- and long-term performance objectives.
Our Comprehensive Approach to Securing Your Acquisitions
OSICS’ Pharma Due Diligence is based on a robust methodology, combining analytical rigor, sector benchmarks, and hands-on experience. From the audit phase, we mobilize experts capable of conducting a comprehensive operational assessment of the asset—evaluating industrial infrastructure, current technologies, the maturity of the quality system, and supply chain resilience.
Each site is assessed on production capacity, compliance with Good Manufacturing Practices (GMP), quality risk management, and readiness for regulatory inspections. We also analyze organizational robustness, middle management strength, and the company’s ability to support a transformation or growth plan. These findings are cross-referenced with performance benchmarks from our global network to objectively position the asset against market standards. This approach provides investors with a precise assessment—not only of the asset’s current state but also of its future potential.
Beyond raw data, our analysis systematically integrates the operational and financial impact of each finding. Each identified risk is placed in perspective with its potential consequences on profitability, future valuation, and the expected ROI timeline. This ability to translate operational insights into actionable financial intelligence gives our clients a decisive advantage.
Identifying Strategic Risks and Actionable Plans
In any acquisition, identifying and precisely evaluating sector-specific risks in pharma/biotech is critical to securing the investment. OSICS Network uses an advanced risk scoring matrix to systematically classify each threat according to its severity, likelihood, and impact on the asset’s future performance.
Regulatory risks are scrutinized with particular attention: inspection history, compliance with international standards, and hidden or emerging non-compliance risks. Likewise, industrial risks (non-robust processes, aging infrastructure, high scrap rates) and organizational risks (governance weaknesses, excessive key talent dependence, change resistance) are systematically mapped.
For each identified risk, OSICS provides concrete, prioritized action plans. These plans outline corrective levers, estimate required investments, and anticipate remediation timelines. Our pragmatic approach equips Private Equity clients with a true decision-support tool: when finalizing their acquisition, they have a clear view of residual risks, required actions, and associated budget impacts. This anticipation capability significantly strengthens their position during final negotiations and in preparing the post-acquisition integration plan.
Maximizing Value through Impact-Oriented Due Diligence
At OSICS, Pharma Due Diligence is not an end in itself, but a springboard for building a post-acquisition value creation strategy. Our approach systematically integrates reflection on Value Drivers and rapid transformation plans (TIP – Transformation & Integration Plan) to implement immediately upon asset integration.
By identifying not only threats but also rapid improvement opportunities, we enable clients to prepare for immediate high-impact initiatives: production line optimization, supply chain streamlining, quality capacity enhancement, or key team reorganization. This proactive stance is essential in Pharma/Biotech, where post-acquisition dynamics strongly influence future valuation.
Our analyses often lead to precise recommendations for accelerating performance gains: CAPEX prioritization, deployment of best industrial practices, functional consolidation between existing sites and new assets. The goal is clear: to secure and rapidly maximize investment value—while laying the foundation for sustainable and profitable growth.
Looking to Better Frame Your Strategic Challenges?
At OSICS, every consulting mission is grounded in a precise understanding of your business goals, sector dynamics, and operational realities. Our tailored approach helps organizations make the right decisions—at the right time, with the right partners.
Why Choose OSICS Network for Your
Pharma & Biotech Due Diligence?
Choosing OSICS means partnering with a team that brings real, field-proven operational expertise—fully aligned with Private Equity’s challenges in Pharma and Biotech. Our consultants are not just analysts: they are former industrial leaders, quality managers, and production directors who deeply understand the complex realities of pharmaceutical environments.
We deliver immediate value to our clients: fast audit capability, factual analysis, actionable recommendations aligned with value optimization goals.
Our global network gives us access to sector comparables and high-performing benchmarks—providing rare analytical depth in every engagement. Our methodologies—combining Risk Scoring, Value Opportunity Mapping, and post-acquisition transformation scenarios—ensure maximum investment process security.
Trusting OSICS for your Pharma Due Diligence means choosing a results-driven approach—where every action is designed to protect your invested capital and accelerate value creation.